India, Aug. 31 -- Ecommerce unicorn DealShare is reportedly in advanced talks to be acquired by online pharmacy Truemeds through a share-swap transaction.

The proposed deal could value DealShare at a little over $90 Mn, a steep fall from its peak valuation of $1.7 Bn in 2022, the Economic Times reported. Entrackr was the first to report that DealShare was in talks for a potential acquisition.

Under the proposed structure, Truemeds is expected to issue shares to DealShare's investors at a valuation of about $600 Mn. The final terms of the transaction are still being worked out.

DealShare and Truemeds did not respond to Inc42's queries till the time of publishing this story. The story will be updated upon receiving a response.

The propo...